Echo Therapeutics major shareholder Purchases $38,060 in Stock (ECTE)
Echo Therapeutics (NASDAQ:ECTE) major shareholder Mark Nordlicht purchased 17,300 shares of Echo Therapeutics stock on the open market in a transaction that occurred on Thursday, June 26th. The stock was purchased at an average price of $2.20 per share, with a total value of $38,060.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Separately, analysts at Feltl & Co. downgraded shares of Echo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 12th.
Shares of Echo Therapeutics (NASDAQ:ECTE) opened at 2.18 on Monday. Echo Therapeutics has a 52-week low of $1.53 and a 52-week high of $4.91. The stock’s 50-day moving average is $1. and its 200-day moving average is $2.91. The company’s market cap is $26.1 million.
Echo Therapeutics (NASDAQ:ECTE) last announced its earnings results on Friday, May 9th. The company reported ($0.23) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.31) by $0.08. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts predict that Echo Therapeutics will post $-0.90 earnings per share for the current fiscal year.
Echo Therapeutics, Inc (NASDAQ:ECTE) is a medical device and specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.